Eli Lilly and Company (NYSE:LLY) Given New $950.00 Price Target at Berenberg Bank

by · The Cerbat Gem

Eli Lilly and Company (NYSE:LLY – Get Free Report) had its target price upped by equities research analysts at Berenberg Bank from $830.00 to $950.00 in a research note issued on Tuesday,MarketScreener reports. The brokerage presently has a “hold” rating on the stock. Berenberg Bank’s price objective points to a potential downside of 10.03% from the stock’s previous close.

Several other equities research analysts also recently weighed in on the company. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. CICC Research lifted their target price on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Daiwa Capital Markets boosted their target price on shares of Eli Lilly and Company from $700.00 to $940.00 in a research report on Monday, November 10th. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $886.00 to $1,104.00 in a report on Monday, November 10th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,064.57.

Check Out Our Latest Stock Report on LLY

Eli Lilly and Company Stock Down 0.2%

Eli Lilly and Company stock opened at $1,055.94 on Tuesday. The business has a fifty day moving average of $895.42 and a two-hundred day moving average of $802.48. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a market cap of $998.27 billion, a P/E ratio of 69.06, a P/E/G ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue was up 53.9% compared to the same quarter last year. During the same period last year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PCG Asset Management LLC boosted its stake in shares of Eli Lilly and Company by 5.4% during the 3rd quarter. PCG Asset Management LLC now owns 465 shares of the company’s stock worth $355,000 after acquiring an additional 24 shares in the last quarter. Payne Capital Management LLC acquired a new position in Eli Lilly and Company in the 3rd quarter worth about $216,000. Investment Research Partners LLC acquired a new position in Eli Lilly and Company in the 3rd quarter worth about $1,321,000. Cambria Investment Management L.P. boosted its position in Eli Lilly and Company by 255.2% during the third quarter. Cambria Investment Management L.P. now owns 1,428 shares of the company’s stock worth $1,090,000 after purchasing an additional 1,026 shares in the last quarter. Finally, Strategic Advocates LLC acquired a new stake in Eli Lilly and Company in the third quarter valued at approximately $132,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read More